ce protein (BCRP). Sofosbuvir is a substrate of P-gp and BCRP. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp or BCRP inhibitors. Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir is a substrate of the breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transporters, while velpatasvir inhibits both BCRP and P-gp. Use caution when administering velpatasvir with cobicistat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); cobicistat is an inhibitor of P-gp and BCRP. Cobicistat is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Conivaptan: Caution is warranted when conivaptan is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Conivaptan is P-glycoprotein (P-gp) inhibitor. Sofosbuvir is a substrate of P-gp. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp inhibitors; however, if these drugs are given together, consider increased monitoring for potential adverse effects. Use caution when administering velpatasvir with conivaptan. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); conivaptan is an inhibitor of P-gp. Conivaptan is also a potent inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Crizotinib: Use caution when administering velpatasvir with crizotinib. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, crizotinib is an inhibitor of the hepatic enzymes CYP3A4 and CYP2B6. Velpatasvir is a substrate of both these enzymes.
Cyclosporine: Use caution when administering velpatasvir with cyclosporine. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). Velpatasvir is also a substrate for the Breast Cancer Resistance Protein (BCRP). Cyclosporine is a BCRP inhibitor. In addition, cyclosporine is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Dabrafenib: Avoid coadministration of velpatasvir with dabrafenib. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; dabrafenib is an inducer of CYP3A4.
Daclatasvir: Do not coadminister velpatasvir with daclatasvir. Taking these drugs together is a duplication of therapy, and may result in adverse effects.
Dalfopristin; Quinupristin: Use caution when administering velpatasvir with dalfopristin; quinupristin. Taking these drugs together may increase velpatasvir plasma concentrations, potential |
